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Conference Summary
W135
Meningococcal
Disease in Africa
1
Epidemic meningococcal disease
has occurred in Africa for approxi-
mately 100 years and has been recog-
nized as a particular problem in sub-
Saharan Africa, “the meningitis belt,”
since 1963. Despite intervention with
plain polysaccharide vaccines, thou-
sands of cases and deaths continue to
occur. The circumstances that have
driven these epidemics of disease
remain poorly understood, but a num-
ber of factors are likely to be impor-
tant, including crowded living condi-
tions, population movements, season-
al factors, and the characteristics of
the meningococci circulating at a
given time. During the latter half of
the 20th century, serogroup A
meningococci have been responsible
for most epidemic disease in Africa;
however, as with other regions of the
world, cases caused by serogroup B,
C, Y, W135, and X meningococci
have been occasionally responsible
for epidemics. Some epidemic disease
outbreaks have been associated with
the annual Hajj pilgrimage (e.g., the
spread of serogroup A meningococci
during the late 1980s and the spread
of W135 meningococci from 2000
onwards). Mass vaccination with
serogroup A/C plain polysaccharide
vaccines has been used to control out-
breaks, once they have been identi-
fied, in a number of African countries.
However, the efficacy of this reactive
approach has been questioned, and the
recent occurrence of W135 epi-
demics, combined with a global short-
age of the polysaccharide vaccines,
creates renewed urgency for a rational
and universal preventive program.
This workshop explored the scien-
tific issues behind the design and
implementation of a vaccine strategy
for the meningitis belt of Africa focus-
ing on the epidemiology of meningo-
coccal isolates. Epidemiologic studies
have provided an increasingly
detailed knowledge of meningococcal
disease in Africa. This knowledge has
led to the identification of three dis-
tinct clonal complexes responsible for
serogroup A disease in Africa (ST-1
complex, ST-4 complex, and ST-5
complex) with successive large-scale
epidemics caused by ST-1 and ST-5
complex. Recent epidemiologic find-
ings have shown that serogroup A
meningococci belonging to the ST-5
complex (ST-5 and ST-7) were still
responsible for most cases and out-
breaks of disease in 2000, 2001, and
2002, with the W135 epidemics
caused by bacteria belonging to the
ST-11 complex. This complex has
previously been associated with
serogroup C disease. However, while
knowledge of the clonal complexes
has provided important information
on meningococcal disease in Africa,
more detailed isolate characterization
has shown that important diversity is
overlooked by relying solely on
sequence type. Despite the availabili-
ty of a number of meningococcal typ-
ing strategies (including pulsed-field
gel electrophoresis, multilocus
enzyme electrophoresis, and 16s
rRNA typing), to date, no portable
method is broadly accepted for identi-
fying subvariants below the level of
clonal complex. Funding for funda-
mental research to improve methods
of analysis of diversity and dynamics
of these populations is an urgent
requirement.
Since 2000, serogroup W135
meningococci (ST-11) have been iso-
lated from sporadic cases in Algeria,
Cameroon, Chad, Senegal, Niger, and
Central African Republic and at the
end of a serogroup Aoutbreak in 2001
and during a large outbreak during
2002 in Burkina Faso. Carriage stud-
ies demonstrated a high rate of car-
riage of W135 in some affected com-
munities in Burkina Faso. Serogroup
X has also been widespread in Africa
(1970–2000) from studies in Mali,
Niger, Burkina Faso, and Ghana.
Serogroup X has been primarily
found in healthy carriers but also in
occasional epidemics.
These studies highlight the impor-
tance of supporting enhanced labora-
tory surveillance throughout the
region to monitor the spread of non-
serogroup A meningococci. Poly-
merase chain reaction may increase
case ascertainment, but basic microbi-
ologic testing on a large scale is
required.
Several studies have been per-
formed on carriage isolates from pil-
grims returning from the Hajj. Since
2000 and the introduction of ST-11
complex, W135 meningococci among
carried isolates in North Africa
(Sudan, Morocco) was documented.
By contrast, despite a small increase
in cases associated with the Hajj, rates
of disease caused by ST-11 W135
meningococci in Europe remained
low since 2000, with some evidence
that most activity was limited to the
Muslim communities.
One study found that the minority
(8%) of W135 (case and carrier) iso-
lates are O-acetylated (Oac+) in the
United Kingdom and that the current-
ly available tetravalent polysaccha-
ride vaccine evokes bactericidal activ-
ity against both Oac+ and Oac- W135
and Y isolates. The relevance of O-
acetylation to vaccine development
remains uncertain.
To plan intervention strategies in
Africa, changes in the major vaccine
antigen (the capsular polysaccharide)
present among epidemic disease iso-
lates should be closely monitored.
Fundamental research to understand
diversity and dynamics of these
important bacterial populations is
required. The recent epidemic of
W135 and substantial numbers of
cases caused by other non-A
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serogroups (X and C particularly)
provide uncertainty about the future
epidemiology of capsule expression
during epidemics. Epidemic
meningococcal disease in Africa
might no longer be thought of as a
peculiarity of serogroup A meningo-
cocci. The central idea from the work-
shop was that a comprehensive vac-
cine (i.e., a multivalent-conjugate)
was the optimal approach to control-
ling epidemic disease in the meningi-
tis belt of Africa. Even this approach
may fail, given the remarkable adapt-
ability of this variable organism.
Further outbreaks of W135, as well as
serogroup A, might occur in the
region, and contingency planning for
control of W135 outbreaks is
required. 
A sustainable vaccine program for
Africa is needed to prevent future epi-
demics. Conjugate vaccines provide
the possibility of generating protec-
tive immunity from infancy and end-
ing epidemic disease. Such vaccines
have now been developed by pharma-
ceutical companies in industrialized
nations. However, the challenge is the
delivery of effective and affordable
vaccines in sub-Saharan Africa, which
has not so far been possible in collab-
oration with major pharmaceutical
manufacturers. Practical and econom-
ic difficulties exist in delivering an
affordable tetravalent ACYW conju-
gate vaccine for Africa, which, as out-
lined above, is an important objective.
The Meningitis Vaccine Project will
support the development of an afford-
able monovalent serogroup A conju-
gate polysaccharide vaccine in part-
nership with a developing country
manufacturer. In the long term, this
approach allows the possibility of sus-
tainable prevention of epidemics in
the region and is of great importance.
This workshop concluded that a
monovalent serogroup A strategy
could leave the population exposed to
the risk for further non-A epidemics
and that strategies that include other
serogroups, particularly W135, need
to be put in place as soon as is possi-
ble. 
Development of an affordable vac-
cine for Africa cannot be achieved
quickly. Discussion of the urgent
issue of vaccines for control of epi-
demics of meningococcal disease in
the next few years was not possible
during the workshop. The current
polysaccharide vaccine shortages
raise the possibility that epidemic
meningococcal disease continue with
no intervention available. ACYW-
conjugate vaccines are in develop-
ment by several major vaccine manu-
facturers; however, without a market
to drive production of millions of
doses for sub-Saharan Africa, many
more people might die before an
affordable vaccine can be delivered
by the Meningitis Vaccine Project.
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